TRAW (Traws Pharma) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRAW Traws Pharma Inc TRAW
41 GF Score
Price $0.50
GF Value $9.32
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

TRAW
41GF Score
Traws Pharma Inc TRAW
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.50 is trading 94.6% below its estimated GF Value™ of $9.32. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $9.32 vs. price of $0.50 (94.6% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company based in the United States that develops small-molecule therapies for viral diseases and cancer. Its lead antiviral candidates include tivoxavir marboxil, an oral influenza antiviral, and ratutrelvir, a protease inhibitor being developed for COVID-19. The company also develops narazaciclib, a CDK inhibitor for oncology indications, and rigosertib, which targets advanced myelodysplastic syndromes. Traws Pharma advances these programs through preclinical and clinical trials, focusing on viruses that are difficult to treat or resistant to existing therapies. The company has no approved products and generates revenue primarily through collaboration and licensing agreements rather than product sales. Its operations center on research and development, and it relies on partnerships and financing to fund its clinical programs.
41GF Score

Get the complete analysis for TRAW

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price
$9.32
GF Value